Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study
Oxidative stress may promote chronic inflammation and contribute to accelerated atherogenesis in patients with coronary artery disease (CAD). Sulodexide, a glycosaminoglycan consisting primarily of heparin, has been shown to affect oxidative stress in experimental settings. The purpose of this pilot...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor 2009-12, Vol.15 (12), p.CR618-CR623 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | CR623 |
|---|---|
| container_issue | 12 |
| container_start_page | CR618 |
| container_title | Medical science monitor |
| container_volume | 15 |
| creator | Bilinska, Maria Wolszakiewicz, Jadwiga Duda, Monika Janas, Jadwiga Beresewicz, Andrzej Piotrowicz, Ryszard |
| description | Oxidative stress may promote chronic inflammation and contribute to accelerated atherogenesis in patients with coronary artery disease (CAD). Sulodexide, a glycosaminoglycan consisting primarily of heparin, has been shown to affect oxidative stress in experimental settings. The purpose of this pilot study was to determine the effect of sulodexide administration on oxidative stress, inflammation and plasma lipids in patients with proven stable CAD.
Fifty-six optimally treated male CAD patients (pts), mean age 57+/-6 yrs, were randomized to either 8 weeks of sulodexide treatment (SUL, n=28), or to a control group (n=28). At baseline and at the end of the study, all pts underwent full clinical and standard laboratory plasma level assessment of lipids, markers of inflammation, and 8-isoprostane, as a sensitive index of oxidative stress.
At entry the 2 groups did not differ significantly in terms of age, coronary risk factors, clinical status and concomitant medication. SUL treatment appeared to be safe and caused a significant decrease in the level of plasma 8-isoprostane (77.4 vs 44.5 pg/ml, p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734161287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734161287</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-eda883fc0e3689d65c34eee715f13445d8fb10eb0fe897452da3f5a648eb75d53</originalsourceid><addsrcrecordid>eNo1kE1LxDAQhosg7rr6FyQ3L1tImo-m3pbFL1jwoueSNhONpEltUrX_3ojr6RmYZ16Y96RYE8FoSWuOV8V5jO8YV1JgflasSNMwUdFqXSw7n2z4tlol-wlI9Rk2LSgYFGcXNOQVbJFCr27pQ1SD9eF3VH6LrEdjPgOfIvqy6Q3FpDoHqA9T8GpakJoSZGgbQUW4ySmjdSFlb9bLRXFqlItweeSmeLm7fd4_lIen-8f97lCOFcGpBK2kpKbHQIVstOA9ZQBQE24IZYxraTqCocMGZFMzXmlFDVeCSehqrjndFNd_ueMUPmaIqR1s7ME55SHMsa0pI4JUss7m1dGcuwF0O052yG-0_23RHwqaaD0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734161287</pqid></control><display><type>article</type><title>Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bilinska, Maria ; Wolszakiewicz, Jadwiga ; Duda, Monika ; Janas, Jadwiga ; Beresewicz, Andrzej ; Piotrowicz, Ryszard</creator><creatorcontrib>Bilinska, Maria ; Wolszakiewicz, Jadwiga ; Duda, Monika ; Janas, Jadwiga ; Beresewicz, Andrzej ; Piotrowicz, Ryszard</creatorcontrib><description>Oxidative stress may promote chronic inflammation and contribute to accelerated atherogenesis in patients with coronary artery disease (CAD). Sulodexide, a glycosaminoglycan consisting primarily of heparin, has been shown to affect oxidative stress in experimental settings. The purpose of this pilot study was to determine the effect of sulodexide administration on oxidative stress, inflammation and plasma lipids in patients with proven stable CAD.
Fifty-six optimally treated male CAD patients (pts), mean age 57+/-6 yrs, were randomized to either 8 weeks of sulodexide treatment (SUL, n=28), or to a control group (n=28). At baseline and at the end of the study, all pts underwent full clinical and standard laboratory plasma level assessment of lipids, markers of inflammation, and 8-isoprostane, as a sensitive index of oxidative stress.
At entry the 2 groups did not differ significantly in terms of age, coronary risk factors, clinical status and concomitant medication. SUL treatment appeared to be safe and caused a significant decrease in the level of plasma 8-isoprostane (77.4 vs 44.5 pg/ml, p<0.0001) compared with controls (75.7 vs 68.3 pg/ml, p=NS). In contrast, neither LDL cholesterol (2.71 vs 2.72 mmol/l) and triglycerides (1.38 vs 1.43 mmol/l), nor markers of inflammation - fibrinogen (3.7 vs 3.6 g/l), C-reactive protein (0.14 vs 0.13 mg/l), leukocyte count (6.33 vs 6.32x10(9)/l) - were affected by SUL treatment.
Sulodexide administration resulted in significant reduction in oxidative stress in stable CAD patients, and neither the changes in cholesterol metabolism nor in systemic inflammation underlay this effect.</description><identifier>EISSN: 1643-3750</identifier><identifier>PMID: 19946232</identifier><language>eng</language><publisher>United States</publisher><subject>Antioxidants - therapeutic use ; Biomarkers - blood ; C-Reactive Protein - metabolism ; Coronary Artery Disease - blood ; Coronary Artery Disease - drug therapy ; Dinoprost - analogs & derivatives ; Dinoprost - blood ; Fibrinogen - metabolism ; Glycosaminoglycans - therapeutic use ; Humans ; Inflammation - drug therapy ; Leukocyte Count ; Lipids - blood ; Male ; Middle Aged ; Oxidative Stress - drug effects ; Pilot Projects</subject><ispartof>Medical science monitor, 2009-12, Vol.15 (12), p.CR618-CR623</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19946232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bilinska, Maria</creatorcontrib><creatorcontrib>Wolszakiewicz, Jadwiga</creatorcontrib><creatorcontrib>Duda, Monika</creatorcontrib><creatorcontrib>Janas, Jadwiga</creatorcontrib><creatorcontrib>Beresewicz, Andrzej</creatorcontrib><creatorcontrib>Piotrowicz, Ryszard</creatorcontrib><title>Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>Oxidative stress may promote chronic inflammation and contribute to accelerated atherogenesis in patients with coronary artery disease (CAD). Sulodexide, a glycosaminoglycan consisting primarily of heparin, has been shown to affect oxidative stress in experimental settings. The purpose of this pilot study was to determine the effect of sulodexide administration on oxidative stress, inflammation and plasma lipids in patients with proven stable CAD.
Fifty-six optimally treated male CAD patients (pts), mean age 57+/-6 yrs, were randomized to either 8 weeks of sulodexide treatment (SUL, n=28), or to a control group (n=28). At baseline and at the end of the study, all pts underwent full clinical and standard laboratory plasma level assessment of lipids, markers of inflammation, and 8-isoprostane, as a sensitive index of oxidative stress.
At entry the 2 groups did not differ significantly in terms of age, coronary risk factors, clinical status and concomitant medication. SUL treatment appeared to be safe and caused a significant decrease in the level of plasma 8-isoprostane (77.4 vs 44.5 pg/ml, p<0.0001) compared with controls (75.7 vs 68.3 pg/ml, p=NS). In contrast, neither LDL cholesterol (2.71 vs 2.72 mmol/l) and triglycerides (1.38 vs 1.43 mmol/l), nor markers of inflammation - fibrinogen (3.7 vs 3.6 g/l), C-reactive protein (0.14 vs 0.13 mg/l), leukocyte count (6.33 vs 6.32x10(9)/l) - were affected by SUL treatment.
Sulodexide administration resulted in significant reduction in oxidative stress in stable CAD patients, and neither the changes in cholesterol metabolism nor in systemic inflammation underlay this effect.</description><subject>Antioxidants - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>C-Reactive Protein - metabolism</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Dinoprost - analogs & derivatives</subject><subject>Dinoprost - blood</subject><subject>Fibrinogen - metabolism</subject><subject>Glycosaminoglycans - therapeutic use</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Leukocyte Count</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oxidative Stress - drug effects</subject><subject>Pilot Projects</subject><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAQhosg7rr6FyQ3L1tImo-m3pbFL1jwoueSNhONpEltUrX_3ojr6RmYZ16Y96RYE8FoSWuOV8V5jO8YV1JgflasSNMwUdFqXSw7n2z4tlol-wlI9Rk2LSgYFGcXNOQVbJFCr27pQ1SD9eF3VH6LrEdjPgOfIvqy6Q3FpDoHqA9T8GpakJoSZGgbQUW4ySmjdSFlb9bLRXFqlItweeSmeLm7fd4_lIen-8f97lCOFcGpBK2kpKbHQIVstOA9ZQBQE24IZYxraTqCocMGZFMzXmlFDVeCSehqrjndFNd_ueMUPmaIqR1s7ME55SHMsa0pI4JUss7m1dGcuwF0O052yG-0_23RHwqaaD0</recordid><startdate>200912</startdate><enddate>200912</enddate><creator>Bilinska, Maria</creator><creator>Wolszakiewicz, Jadwiga</creator><creator>Duda, Monika</creator><creator>Janas, Jadwiga</creator><creator>Beresewicz, Andrzej</creator><creator>Piotrowicz, Ryszard</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200912</creationdate><title>Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study</title><author>Bilinska, Maria ; Wolszakiewicz, Jadwiga ; Duda, Monika ; Janas, Jadwiga ; Beresewicz, Andrzej ; Piotrowicz, Ryszard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-eda883fc0e3689d65c34eee715f13445d8fb10eb0fe897452da3f5a648eb75d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antioxidants - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>C-Reactive Protein - metabolism</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Dinoprost - analogs & derivatives</topic><topic>Dinoprost - blood</topic><topic>Fibrinogen - metabolism</topic><topic>Glycosaminoglycans - therapeutic use</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Leukocyte Count</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oxidative Stress - drug effects</topic><topic>Pilot Projects</topic><toplevel>online_resources</toplevel><creatorcontrib>Bilinska, Maria</creatorcontrib><creatorcontrib>Wolszakiewicz, Jadwiga</creatorcontrib><creatorcontrib>Duda, Monika</creatorcontrib><creatorcontrib>Janas, Jadwiga</creatorcontrib><creatorcontrib>Beresewicz, Andrzej</creatorcontrib><creatorcontrib>Piotrowicz, Ryszard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilinska, Maria</au><au>Wolszakiewicz, Jadwiga</au><au>Duda, Monika</au><au>Janas, Jadwiga</au><au>Beresewicz, Andrzej</au><au>Piotrowicz, Ryszard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2009-12</date><risdate>2009</risdate><volume>15</volume><issue>12</issue><spage>CR618</spage><epage>CR623</epage><pages>CR618-CR623</pages><eissn>1643-3750</eissn><abstract>Oxidative stress may promote chronic inflammation and contribute to accelerated atherogenesis in patients with coronary artery disease (CAD). Sulodexide, a glycosaminoglycan consisting primarily of heparin, has been shown to affect oxidative stress in experimental settings. The purpose of this pilot study was to determine the effect of sulodexide administration on oxidative stress, inflammation and plasma lipids in patients with proven stable CAD.
Fifty-six optimally treated male CAD patients (pts), mean age 57+/-6 yrs, were randomized to either 8 weeks of sulodexide treatment (SUL, n=28), or to a control group (n=28). At baseline and at the end of the study, all pts underwent full clinical and standard laboratory plasma level assessment of lipids, markers of inflammation, and 8-isoprostane, as a sensitive index of oxidative stress.
At entry the 2 groups did not differ significantly in terms of age, coronary risk factors, clinical status and concomitant medication. SUL treatment appeared to be safe and caused a significant decrease in the level of plasma 8-isoprostane (77.4 vs 44.5 pg/ml, p<0.0001) compared with controls (75.7 vs 68.3 pg/ml, p=NS). In contrast, neither LDL cholesterol (2.71 vs 2.72 mmol/l) and triglycerides (1.38 vs 1.43 mmol/l), nor markers of inflammation - fibrinogen (3.7 vs 3.6 g/l), C-reactive protein (0.14 vs 0.13 mg/l), leukocyte count (6.33 vs 6.32x10(9)/l) - were affected by SUL treatment.
Sulodexide administration resulted in significant reduction in oxidative stress in stable CAD patients, and neither the changes in cholesterol metabolism nor in systemic inflammation underlay this effect.</abstract><cop>United States</cop><pmid>19946232</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1643-3750 |
| ispartof | Medical science monitor, 2009-12, Vol.15 (12), p.CR618-CR623 |
| issn | 1643-3750 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734161287 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Antioxidants - therapeutic use Biomarkers - blood C-Reactive Protein - metabolism Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Dinoprost - analogs & derivatives Dinoprost - blood Fibrinogen - metabolism Glycosaminoglycans - therapeutic use Humans Inflammation - drug therapy Leukocyte Count Lipids - blood Male Middle Aged Oxidative Stress - drug effects Pilot Projects |
| title | Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T03%3A46%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antioxidative%20activity%20of%20sulodexide,%20a%20glycosaminoglycan,%20in%20patients%20with%20stable%20coronary%20artery%20disease:%20a%20pilot%20study&rft.jtitle=Medical%20science%20monitor&rft.au=Bilinska,%20Maria&rft.date=2009-12&rft.volume=15&rft.issue=12&rft.spage=CR618&rft.epage=CR623&rft.pages=CR618-CR623&rft.eissn=1643-3750&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E734161287%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734161287&rft_id=info:pmid/19946232&rfr_iscdi=true |